Teva Pharmaceutical has announced the U.S. Food and Drug Administration's approval of an Abbreviated New Drug Application, potentially unlocking significant sales opportunities by introducing a generic alternative to the branded market. While immediate market share gains are anticipated, investors are advised to monitor potential patent litigation risks that could delay the product's commercial launch.